RIM
PRTK

Rainier Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Rainier Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.37M Sell
76,490
-2,430
-3% -$50.7K 0.58% 72
2017
Q3 		$1.98M Sell
78,920
-6,870
-8% -$160K 0.47% 95
2017
Q2 		$2.07M Buy
85,790
+6,620
+8% +$146K 0.41% 105
2017
Q1 		$1.52M Buy
+79,170
New +$1.25M 0.17% 147

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Rainier Investment Management's PRTK Position: Q4 2017 in Review

Rainier Investment Management reduced its Paratek Pharmaceuticals, Inc. (PRTK) stake by 3.1% in Q4 2017, selling an estimated $50.7K and leaving 76,490 shares worth $1.37M. The position accounts for 0.58% of the portfolio, ranked #72.

Rainier Investment Management first reported a position in PRTK in Q1 2017 and has held it in 4 quarters since. The position peaked at $2.07M in Q2 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Rainier Investment Management held 76,490 shares of Paratek Pharmaceuticals, Inc. worth $1.37M as of Q4 2017.
  • Rainier Investment Management sold 2,430 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $50.7K.
  • Paratek Pharmaceuticals, Inc. made up 0.58% of Rainier Investment Management's portfolio in Q4 2017, its #72 holding.
  • Rainier Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and has held it in 4 quarters since.
  • Rainier Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $2.07M in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Rainier Investment Management's 13F filing for Q4 2017, filed 2 Feb 2018.